HRAS mutation	Squamous Cell Carcinoma of Head and Neck	HRAS mutation	Squamous Cell Carcinoma of Head and Neck	tipifarnib Sensitive: B - Late Trials tipifarnib Sensitive : B	tipifarnib Sensitive: B - Late Trials tipifarnib Sensitive : B
HRAS mutation	Urothelial Cancer	HRAS mutation	Urothelial Cancer	tipifarnib Sensitive: C2 – Inclusion Criteria tipifarnib Sensitive : C2	tipifarnib Sensitive: C2 – Inclusion Criteria tipifarnib Sensitive : C2
HRAS mutation	Salivary Gland Cancer	HRAS mutation	Salivary Gland Cancer	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
HRAS mutation	Squamous Cell Carcinoma of Head and Neck	HRAS mutation	Squamous Cell Carcinoma of Head and Neck	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
HRAS mutation	Solid Tumor	HRAS mutation	Solid Tumor	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3
HRAS mutation	Melanoma	HRAS mutation	Melanoma	cobimetinib + RG6185 Sensitive: C3 – Early Trials cobimetinib + RG6185 Sensitive : C3	cobimetinib + RG6185 Sensitive: C3 – Early Trials cobimetinib + RG6185 Sensitive : C3
HRAS mutation	Rhabdomyosarcoma	HRAS mutation	Rhabdomyosarcoma	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D
HRAS mutation	Endometrial Cancer	HRAS mutation	Endometrial Cancer	AZ 628 Sensitive: D – Preclinical AZ 628 Sensitive : D	AZ 628 Sensitive: D – Preclinical AZ 628 Sensitive : D
HRAS mutation	Endometrial Cancer	HRAS mutation	Endometrial Cancer	PD-0325901 Sensitive: D – Preclinical PD-0325901 Sensitive : D	PD-0325901 Sensitive: D – Preclinical PD-0325901 Sensitive : D
HRAS mutation	Bladder Cancer	HRAS mutation	Bladder Cancer	FL118 Sensitive: D – Preclinical FL118 Sensitive : D	FL118 Sensitive: D – Preclinical FL118 Sensitive : D
HRAS mutation	Rhabdomyosarcoma	HRAS mutation	Rhabdomyosarcoma	trametinib + tipifarnib Sensitive: D – Preclinical trametinib + tipifarnib Sensitive : D	trametinib + tipifarnib Sensitive: D – Preclinical trametinib + tipifarnib Sensitive : D

HRAS mutation

Associations